Antibody-drug conjugates (ADCs) are a promising class of targeted cancer therapies, combining the specificity of monoclonal antibodies with the cytotoxic power of chemotherapeutic agents. ADCs have shown significant potential in delivering drugs directly to cancer cells while minimizing the off-target effects. However, predicting the efficacy and toxicity of ADCs in clinical settings remains a significant challenge. Empirical models often fail to accurately capture the complex pharmacokinetics and pharmacodynamics (PKPD) associated with these biotherapeutics.

Overview of the PK/PD model for combined efficacy and toxicity predictions